Enocitabine (NSC-239336, BHAC) is an antileukemic agent closely related to cytarabine. It appears
more resistant to deamination than cytarabine, thus allowing greater in vivo
phosphorylation into an active cytotoxic metabolite. Enocitabine is lipophilic, but the drug does not enter the cerebrospinal fluid and is concentrated in the bone marrow and red blood cells. It can be administered orally and appears to be more effective than the parent compound in preclinical models.
